In the absence of definitive biomarkers, microglial replacement strategies may be most appropriate for genetically defined AD subtypes with mutations in microglia-specific genes (eg, TREM2, SORL1, and HAVCR2), as illustrated in Figure 1. The gene discussed is HAVCR2; the disease is Alzheimer disease.